



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

19 May 2020

Imagion Biosystems' nanoparticles used in viral therapy research

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of the company's nanoparticles in investigating a human immunodeficiency virus type -1 (HIV-1) therapy.

The work, published in the Journal of Virology (March 2020 Volume 94 Issue 6) illustrates how iron oxide nanoparticles could be used in conjunction with viral specific agents to create "a particulate immunogen" that stimulates the body's immune response through neutralizing antibody (NAb) induction. The publication can be download here <https://t.co/CaV8FWfuhX?amp=1>.

"We are very happy to see new biomedical applications being developed from the commercial sale of our PrecisionMRX® brand of nanoparticles," said Bob Proulx, Executive Chairman of Imagion Biosystems. "The COVID-19 pandemic has raised everyone's awareness of the need to develop better therapies and vaccines for viral diseases. Nanoparticles may provide an important role in the development of effective treatments. While we remain focused on our goal of developing the nanoparticles for the detection of cancer through our MagSense™ programs, it is clear there are many potential clinical applications in which our nanoparticles can be applied, and we are keen to identify prospective partners in these areas. Our investment in manufacturability of our nanoparticles puts us in a good position to be a prospective partner or supplier if research leads to commercial applications."

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

This Announcement has been approved by the Executive Chairman.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722